- βInsulin aspart showed no significant difference in birth defects, stillbirth, or other serious pregnancy complications compared to other mealtime insulins
- βReal-world data from nearly 1,840 pregnancies strengthens confidence in insulin aspart's everyday safety profile
- βWomen using insulin aspart had slightly lower HbA1c in the third trimester, suggesting a potential blood sugar benefit late in pregnancy
| Journal | Diabetic medicine : a journal of the British Diabetic Association |
| Year | 2024 |
| Authors | Mathiesen, Alibegovic, Anil |
| PMID | 39115159 |
What Was Studied and Why It Matters
Managing blood sugar during pregnancy with Type 1 diabetes is one of the most challenging balancing acts in medicine. Too high, and there are risks of birth defects and complications. Too low, and dangerous hypoglycemia can occur. Researchers wanted to know whether insulin aspart β a fast-acting mealtime insulin widely used during pregnancy β was safer or more effective than other bolus (mealtime) insulins in real-world conditions, not just controlled clinical trials.
This study analyzed data from nearly 1,840 pregnant women with Type 1 diabetes enrolled in a Diabetes Pregnancy Registry. About 1,434 used insulin aspart, while 406 used other mealtime insulins. This is one of the largest real-world comparisons of its kind.
What the Researchers Found
The headline finding is reassuring: insulin aspart performed just as safely as other mealtime insulins across a wide range of pregnancy outcomes. Researchers looked at serious outcomes including:
- Major birth defects (congenital malformations)
- Stillbirth and newborn death
- Premature delivery
- Pre-eclampsia (dangerous high blood pressure in pregnancy)
- Babies born unusually large (large for gestational age)
- Severe low blood sugar (hypoglycemia) in the mother
None of these outcomes were significantly different between the two groups. That is good news β it means women already using insulin aspart during pregnancy can feel confident in its safety record.
There was one notable difference, however. Women using insulin aspart had slightly lower HbA1c levels during the final stretch of pregnancy (the third trimester) compared to those on other insulins. HbA1c is a measure of average blood sugar over roughly three months β lower is generally better during pregnancy. The difference was small (-0.16 percentage points) but statistically meaningful. Researchers say this finding needs confirmation in future studies before drawing firm conclusions.
What This Means for Real Patients
If you have Type 1 diabetes and are pregnant β or planning to become pregnant β this study offers practical reassurance. Insulin aspart is a commonly prescribed mealtime insulin, and having real-world evidence (not just trial data) supporting its safety is valuable.
Staying well-stocked with your insulin supplies and monitoring equipment is especially critical during pregnancy, when blood sugar needs close, consistent management. MDS Diabetes can help ensure you have reliable access to your insulin pen needles, glucose testing supplies, and other diabetes essentials so managing your care stays one less thing to worry about.
Always work closely with your endocrinologist and OB team to determine the right insulin regimen for your individual pregnancy needs.
Bottom Line
A large real-world study confirms that insulin aspart is as safe as other mealtime insulins for pregnant women with Type 1 diabetes, with no meaningful differences in birth outcomes or complications. A small improvement in late-pregnancy blood sugar control was observed with insulin aspart, which is promising but needs further research to confirm. Women managing Type 1 diabetes through pregnancy can feel reassured by this evidence β and should keep their diabetes supplies consistent and accessible throughout.